HK Stock Market Move | INSILICO (03696) rose by more than 6%. The company is advancing AI-driven early drug discovery and recently reached a strategic cooperation agreement with Hangzhou Tigermed Consulting in AI pharmaceuticals.

INSILICO (03696) surges more than 6%, as of the time of writing, it is up by 6.74% at HK$64.9, with a turnover of HK$131 million. On the news front, on April 20, according to INSILICO's official WeChat account, the company announced a new development in its unified AI framework for drug target discovery: the company has integrated the previously launched Target Identification Pro (TargetPro) with the Target Identification Benchmark 1.0 into a validated system aimed at further enhancing the accuracy, reliability, and scalability of early drug research and development. A recent study published in Scientific Reports shows that this framework has demonstrated outstanding results in benchmarking and real-world target discovery workflows, further demonstrating its value as a standardized AI-driven target identification base. It is worth mentioning that recently, Hangzhou Tigermed Consulting signed a strategic cooperation agreement with INSILICO, and the two parties will carry out long-term strategic cooperation in clinical research of innovative drug products. According to the agreement, Hangzhou Tigermed Consulting will leverage its advantages in clinical research services to provide one-stop, customized professional support for INSILICO's innovative drug products. The services will cover all core areas including clinical monitoring, data management and statistical analysis, medical affairs, pharmacovigilance, and regulatory affairs. Hangzhou Tigermed Consulting will form a specialized team and tailor service solutions based on INSILICO's AI-driven research characteristics. This collaboration signifies a strong alliance between the two parties in AI technology and innovation capabilities in clinical development.